DEF: Penumbra, Inc. Announces Annual Meeting of Stockholders with Key Governance Proposals

Penumbra, Inc. is holding its annual meeting on May 28, 2025, to vote on director elections, auditor ratification, executive compensation, and amendments to the company's charter regarding board declassification and supermajority voting requirements.

Summary

• Penumbra, Inc. will hold its 2025 Annual Meeting of Stockholders on May 28, 2025, at its Alameda, CA campus.
• Stockholders will vote to elect Class I directors, ratify PricewaterhouseCoopers LLP as the independent auditor for the fiscal year ending December 31, 2025, and provide an advisory vote on executive compensation.
• The meeting will also include votes on amendments to the company's Restated Certificate of Incorporation to phase in the declassification of the Board of Directors and eliminate supermajority voting requirements.
• The record date for determining eligible voters is March 31, 2025, with 38,683,650 shares of common stock outstanding and entitled to vote.
• The Board recommends voting for the director nominees, ratification of PwC, approval of executive compensation, and approval of the charter amendments.

Sentiment

Score: 7

Explanation: The document is primarily factual and procedural, outlining the agenda and proposals for the annual meeting. The sentiment is neutral to slightly positive due to the focus on improving corporate governance and aligning with best practices.

Positives

• The proposed amendments to the charter aim to improve corporate governance by increasing accountability to stockholders through annual director elections and eliminating supermajority voting requirements.
• The Board is actively seeking stockholder input and engagement, as demonstrated by the 'Say-on-Pay' vote and communication channels.
• The company has stock ownership guidelines for non-employee directors and the CEO to align their interests with those of stockholders.
• The company has adopted a formal anti-hedging and anti-pledging policy for employees and directors.

Negatives

• Harpreet Grewal, a director, settled litigation with the SEC in 2019 related to violations of securities laws during his time at Constant Contact, resulting in a fine of $350,000 and a permanent injunction from future violations.
• The company deems 1,730,115 shares under the 2014 Equity Incentive Plan and 346,023 shares under the ESPP as not available for issuance as of December 31, 2024, due to not registering the offering of such shares under the Securities Act.

Risks

• Failure to ratify the selection of PricewaterhouseCoopers LLP as the independent registered public accounting firm could require the Board to reconsider its choice.
• If the proposed amendments to the charter are not approved, the Board will remain classified, and supermajority voting requirements will remain in place, potentially hindering corporate governance improvements.
• The company's future executive compensation may not be fully deductible due to limitations under Section 162(m) of the Code.
• The company is subject to a compensation recovery policy in the event of an accounting restatement due to material noncompliance with financial reporting requirements.

Future Outlook

The company is seeking stockholder approval for amendments to its charter to phase in the declassification of the Board of Directors and eliminate supermajority voting requirements, which are expected to enhance corporate governance.

Industry Context

The document reflects a trend in corporate governance towards greater stockholder empowerment through annual director elections and the elimination of supermajority voting requirements, aligning Penumbra with best practices and investor expectations.

Comparison to Industry Standards

• The document mentions a peer group of healthcare equipment, healthcare supplies, healthcare technology, and life sciences tools and services companies used for compensation benchmarking.
• Specific companies in the peer group include 10x Genomics, Lantheus Holdings, Bio-Techne, Merit Medical Systems, Masimo, Neogen, Glaukos, QuidelOrtho, Globus Medical, Shockwave Medical, Inspire Medical Systems, Sotera Health Company, Teladoc Health, and Medpace Holdings.
• The company's revenue and market capitalization are compared to those of the peer group to assess its relative size and performance.

Corporate Governance

Legal Proceedings

• In December 2019, Mr. Grewal settled litigation instituted by the SEC alleging that Mr. Grewal violated the antifraud provisions of Section 17(a) of the Securities Act of 1933, as amended (the Securities Act), Section 10(b) of the Exchange Act and Rule 10b-5 promulgated under the Exchange Act, and violated, or aided and abetted the violation of, the reporting, record-keeping and internal controls requirements of Section 13(a), Section 13(b)(2)(A) and related rules under the Exchange Act in connection with his position at Constant Contact.
• Without admitting or denying the SECs allegations, Mr. Grewal consented to the entry of a Final Judgment that permanently enjoined him from future violations of Section 17(a) of the Securities Act and from aiding and abetting future violations of Section 13(a) or Section 13(b)(2)(A) of the Exchange Act, and required him to pay a fine of $350,000, including a $100,000 civil penalty.

Related Party Transactions

• Aidan Elsesser, the son of Adam Elsesser, our Chairman, Chief Executive Officer and President, is a non-executive employee of Penumbra and received employment compensation in excess of $120,000 in 2024, and we expect that such employee will receive employment compensation in excess of $120,000 in 2025.

Stakeholder Impact

• Approval of the proposed charter amendments could enhance stockholder rights and influence over corporate governance.
• The advisory vote on executive compensation allows stockholders to express their views on the company's pay practices.
• The election of directors will determine the composition of the Board and its ability to oversee the company's strategy and operations.

Next Steps

• Stockholders are encouraged to vote on the proposals outlined in the proxy statement.
• The company will hold its Annual Meeting of Stockholders on May 28, 2025.
• The company will file a Form 8-K with the SEC to report the final voting results of the Annual Meeting.

Key Dates

Keywords

proxy statement, annual meeting, stockholders, board of directors, executive compensation, corporate governance, PricewaterhouseCoopers, director election, charter amendment, declassification, supermajority voting